Geneoscopy, a St. Louis, MO-based life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, raised $105M in Series C funding.
The round was led by Bio-Rad Laboratories (NYSE: BIO and BIO.B) with participation from Petrichor, Labcorp (NYSE: LH), Morningside Ventures, Lightchain Capital, NT Investments, Granger Management and Mercy Health, Tri Locum Partners, and others.
The company intends to use the funds to continue investing in its innovative pipeline of diagnostic tests for inflammatory bowel disease, addressing a critical unmet medical need.
Geneoscopy is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy aims to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Its FDA-approved ColoSense test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with universities and biopharmaceutical companies, it is also developing diagnostic tests for treatment selection and therapy monitoring in other GI disease areas.
FinSMEs
08/01/2025